Dr. Taylor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
Kansas City, KS 66160Phone+1 913-588-7564Fax+1 913-588-7625
Summary
- Dr. John Taylor is an urologist in Kansas City, KS and is affiliated with multiple hospitals in the area, including The University of Kansas Hospital and Truman Medical Center-Hospital Hill. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice 23 years. He specializes in surgical oncology.
Clinical Expertise
- Urothelial carcinoma, Bladder cancer
Education & Training
- University of ConnecticutMS, Clinical & Translational Research, 2010
- University of ConnecticutM.S., Clinical and Translational Research, 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1996 - 2000
- New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1994 - 1996
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1994
- Lafayette CollegeA.B., Biology, 1990
Certifications & Licensure
- NY State Medical License 1997 - Present
- KS State Medical License 2016 - 2025
- MO State Medical License 2017 - 2025
- CT State Medical License 2003 - 2016
- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
- Best Doctors in America Castle Connelly, 2011-2016
- Best Doctors for the Greater Hartford Area Hartford Magazine, 2009
- Join now to see all
Clinical Trials
- Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors Start of enrollment: 2020 Nov 25
- Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors Start of enrollment: 2019 May 19
Publications & Presentations
PubMed
- 24 citationsTargeting Major Signaling Pathways of Bladder Cancer with Phytochemicals: A Review.Connor Chestnut, Dharmalingam Subramaniam, Prasad Dandawate, Subhash Padhye, John A. Taylor
Nutrition and Cancer. 2020-12-11 - 33 citationsThe Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition.Sanket J. Mishra, Weiya Liu, Kristin Beebe, Monimoy Banerjee, Caitlin N. Kent
Journal of Medicinal Chemistry. 2021-01-11 - 138 citationsWhat Is the Significance of Variant Histology in Urothelial CarcinomaNiyati Lobo, Shahrokh F. Shariat, Charles C. Guo, Mario I. Fernández, Wassim Kassouf
European Urology Focus. 2020-07-15
Journal Articles
- Innovation in bladder cancer immunotherapyGrossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA, Ingersoll MA, J Immunother, 1/1/2016
- Urethral duct invasion in female urethral melanomaUrban J, Bayart CB, Taylor JA, Hegde U, Forouhar F, Dadras SS, Human Pathology: Case Reports, 1/1/2016
- Collaborating to Move Research Forward: Proceedings from the 10th Annual Bladder Cancer Think TankKamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor JA, Williams SB, Quale DZ, Rosenber..., Bladder Cancer, 1/1/2016
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Osteopontin – a potential marker for chemotherapy resistance in bladder cancerGibson N, Choudhary D, Pilbeam CC, Taylor JA, J Urol, 1/1/2016
- Potential role of G1P3 in development of chemoresistance in high grade bladder cancerTaylor JA, American Urological Association Annual Meeting, Bladder Cancer Basic Science Session, San Diego, CA, 1/1/2016
- Osteopontin – a potential marker for chemotherapy resistance in bladder cancerTaylor JA, American Urological Association Annual Meeting, Bladder Cancer Basic Science Session, San Diego, CA, 1/1/2016
- Join now to see all
Lectures
- Management of high grade non-muslce invasive bladder cancerSan Diego, CA - 1/1/2016
- Preclinical Modeling of Bladder Cancer; Potential Role of MIF InhibitionUniversity of Kansas, Cancer Center - 1/1/2015
- Bladder Cancer, Nodal Metastasis and CD62L A Potential Marker?Montefiore Medical Center - 1/1/2015
- Join now to see all
Other
- GRS Teaching SlidesTaylor JA, American Geriatrics Society
http://www.geriatricscareonline.org
NY - 1/1/2013
Press Mentions
- 2019 Urology Care Foundation Research Scholar Awardees AnnouncedMarch 21st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: